Resilience & Innovation: Goodwin Life Sciences in 2024
The life sciences industry showed strong resilience in 2024, marked by increased IPO and M&A activity as big pharma sought to expand pipelines amid favorable valuations.
Goodwin's global and fully integrated life sciences practice guided clients through transformative transactions, strategic partnerships, and innovative deals at every stage of their life cycle. This Year in Review celebrates our clients’ creativity and accomplishments, as well as our collaboration with industry leaders who continue to push the boundaries of science and medicine. Looking ahead, we remain steadfast in our commitment to guiding and supporting our clients as they chart new paths in the evolving life sciences landscape in 2025.
By The Numbers
230+
Financing (VC) Transactions for $14 Billion+
55+
M&A Transactions for $35 Billion+
75+
Equity Offerings (including initial public offerings and follow-on offerings) for $11 Billion+ (Representation of both issuers and underwriters)
60+
Collaboration Transactions for Over $14 Billion+
50+
Commercial Stage Clients on IP Due Diligence and Patent Strategy
200+
Clinical Stage Clients on IP Due Diligence and Patent Strategy
Our Global Recognition
Notable Deals
Regulatory Initiatives
Rare Disease Initiative
Our rare disease initiative works with biotech, pharmaceutical, medical technology, and diagnostic companies and their investors, partners, and key stakeholders focused on developing solutions for countless rare medical conditions.
Inflation Reduction Act
Our resource covers updates and analysis about the Inflation Reduction Act and the ways it could change how government pays for pharmaceuticals and biologics.
Laboratory Developed Tests
We provide foundational materials, legislative and regulatory history, and updates and analyses regarding initiatives to increase oversight over laboratory developed tests (LDTs).
A Look Ahead in Life Sciences 2025
Read our overview of key developments in the legal, regulatory, and compliance landscape for the life sciences, medtech, and diagnostic industries.
